Evidence map›Paper›PMID 42182407›Full record

ArticlebioRxiv : the preprint server for biology2026

Drug design using unique conformations to preferentially target a specific site on collagen-bound MMP1.

Anthony Nash, Chase Harms, Susanta K Sarkar

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Anthony NashSchool of Molecular Sciences, Arizona State University, Tempe, AZ.
Chase HarmsSchool of Molecular Sciences, Arizona State University, Tempe, AZ.
Susanta K SarkarSchool of Molecular Sciences, Arizona State University, Tempe, AZ.ORCID 0000-0002-6858-6912

Funding

Allosteric control of collagen fibril degradation by matrix metalloprotease-1R01GM145210 · NIGMS · COLORADO SCHOOL OF MINES · PI SARKAR, SUSANTA KUMAR · 2022 to 2025
$1.2M
NIGMS NIH HHS R01 GM145210
6 · The paper itself

Abstract

Precise site-specific drug design remains a challenge in structure-based drug discovery. Most existing approaches screen for ligands to target binding pockets on a protein surface based on static structures obtained from techniques such as X-ray, NMR, cryo-EM, and AlphaFold. However, the structure-function paradigm is, in reality, a structure-dynamics-function relationship that determines a protein's binding and activity. As such, drug screening or design without evaluating binding competition across the protein surface or considering the receptor's dynamic, substrate-dependent conformational states is incomplete. Substrate-specific unique protein conformations are underexplored and offer novel opportunities for selective therapeutic targeting, though systematic workflows for identifying and exploiting such sites remain limited. Previously, we showed that collagen alters matrix metalloprotease-1 (MMP1) dynamics and that R405 is an allosteric residue on the MMP1 surface that exhibits strong dynamic correlations with its active site. Here, we present a substrate-specific allosteric drug-design framework that targets specific sites on a protein, using collagen-bound MMP1 as a model system. We determined the conformational dynamics of free and collagen-bound MMP1 using all-atom molecular dynamics (MD) simulations and categorized conformations into clusters of similar conformations. We then compared and identified unique conformations that occur only in collagen-bound MMP1 to design drugs against them using a machine-learning approach. The top three unique clusters were used to generate approximately 150,000 candidate compounds that were then screened against both the R405-centered region and all detectable binding pockets across the MMP1 surface. We have found several compounds that bind preferentially around R405 by at least 0.3 kcal/mol relative to competing sites across the surface. This strategy establishes a generalizable framework for designing ligands that preferentially target substrate-specific allosteric sites, providing new opportunities for precision therapeutics that modulate proteins in their biologically relevant functional states.

Indexed as

collagenMMP1Substrate-specific allosterysubstrate-specific drug design

Identifiers

PMID42182407
PMCPMC13192829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.